| __timestamp | Viatris Inc. | Xenon Pharmaceuticals Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 1499100000 | 5496000 |
| Thursday, January 1, 2015 | 1923500000 | 9786000 |
| Friday, January 1, 2016 | 2351400000 | 6792000 |
| Sunday, January 1, 2017 | 2564000000 | 7313000 |
| Monday, January 1, 2018 | 2397300000 | 8382000 |
| Tuesday, January 1, 2019 | 2503400000 | 10803000 |
| Wednesday, January 1, 2020 | 3344600000 | 12944000 |
| Friday, January 1, 2021 | 4529200000 | 21967000 |
| Saturday, January 1, 2022 | 4179100000 | 32810000 |
| Sunday, January 1, 2023 | 4650100000 | 46542000 |
Data in motion
In the competitive landscape of pharmaceuticals, understanding operational efficiency is crucial. Over the past decade, Viatris Inc. and Xenon Pharmaceuticals Inc. have showcased contrasting strategies in managing their Selling, General, and Administrative (SG&A) expenses. Viatris Inc., a global healthcare giant, has seen its SG&A expenses grow by over 200% from 2014 to 2023, peaking at approximately $4.65 billion. This reflects its expansive operations and market reach. In contrast, Xenon Pharmaceuticals Inc., a smaller player, has maintained a leaner approach, with SG&A expenses increasing by around 750% but still remaining under $50 million in 2023. This stark difference highlights the diverse strategies employed by large and small pharmaceutical companies in managing operational costs. As the industry evolves, these insights provide a window into how companies balance growth with efficiency.
Breaking Down SG&A Expenses: Zoetis Inc. vs Viatris Inc.
Alnylam Pharmaceuticals, Inc. and Viatris Inc.: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Xenon Pharmaceuticals Inc.
SG&A Efficiency Analysis: Comparing Viatris Inc. and BioMarin Pharmaceutical Inc.
Selling, General, and Administrative Costs: Viatris Inc. vs Ultragenyx Pharmaceutical Inc.
Operational Costs Compared: SG&A Analysis of Viatris Inc. and Corcept Therapeutics Incorporated
Who Optimizes SG&A Costs Better? Viatris Inc. or CRISPR Therapeutics AG
Cost Management Insights: SG&A Expenses for Viatris Inc. and BioCryst Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Insmed Incorporated or Xenon Pharmaceuticals Inc.
Axsome Therapeutics, Inc. and Xenon Pharmaceuticals Inc.: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Verona Pharma plc and Xenon Pharmaceuticals Inc.
Selling, General, and Administrative Costs: Amneal Pharmaceuticals, Inc. vs Xenon Pharmaceuticals Inc.